Surpass Medical

Next-generation Flow Diversion Technology

Health Tech & Life Sciences
Acquired (Inactive) by Stryker Corporation on Oct 2012 - closed due to acquisition

Company Overview

Snapshot

Founded in September 2005 by Ygael Grad, Surpass Medical operated with 1–10 employees. The company was acquired by Stryker Corporation in October 2012.

Business overview

Surpass Medical specializes in developing and commercializing next-generation flow diversion technology for treating brain aneurysms. Its core product, the Surpass NeuroEndoGraft, is a minimally invasive catheter-based device designed to occlude aneurysms by redirecting blood flow, promoting clotting, and remodeling the arterial lumen. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories, serving healthcare providers.

Strategic signal

In October 2012, Surpass Medical was acquired by Stryker Corp. for $135 million. This acquisition validated Surpass Medical's flow diversion technology for brain aneurysms and signaled a strategic move by Stryker to enhance its neurovascular portfolio, indicating a significant market interest in advanced minimally invasive treatments for intracranial aneurysms.

Company Intelligence Q&A

What is Surpass Medical's primary technology?
Surpass Medical develops a next-generation flow diversion technology, the Surpass NeuroEndoGraft, which uses a unique mesh design and delivery system to treat brain aneurysms by redirecting blood flow and promoting clotting.
When was Surpass Medical founded?
Surpass Medical was founded in September 2005.
Who founded Surpass Medical?
Surpass Medical was founded by Ygael Grad.
When was Surpass Medical acquired?
Surpass Medical was acquired by Stryker Corporation in October 2012.
What was the acquisition amount for Surpass Medical?
Stryker Corp. purchased Surpass Medical for $135 million in October 2012, as reported by MLive.com.

External links